PMID: 8588238Dec 1, 1995Paper

Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations

Therapeutic Drug Monitoring
R W YatscoffJ Zimmerman

Abstract

Rapamycin (RAPA) is a potent immunosuppressive drug that is presently undergoing clinical trials. The most of the drug is sequestered in erythrocytes resulting in whole blood concentrations being considerably higher than plasma concentrations. The drug is metabolized by the same P450 3A enzyme that is involved in the metabolism of cyclosporine and tacrolimus. Structural elucidation of RAPA metabolites is required. The drug has a relatively long half-life in both humans and animals with 24-h trough concentrations being within the analytic range of high-performance liquid chromatography (HPLC) when immunosuppressive doses are administered. For RAPA, a proportionality is exhibited between trough concentrations and dose. In animal transplant models, trough concentrations of the drug appear to be related to immunosuppressive efficacy and drug-related side effects. The studies described here should provide the basis for establishment of therapeutic monitoring protocols for the drug.

Citations

Mar 1, 2002·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Martin OberhoffKarl R Karsch
Dec 7, 2011·European Journal of Clinical Pharmacology·Jürg ReichenJoan Korth-Bradley
Mar 30, 2007·Cancer Chemotherapy and Pharmacology·Jaime A YáñezNeal M Davies
Oct 1, 1996·Clinical Biochemistry·S J Soldin
Mar 1, 1997·Clinical Biochemistry·K L NapoliB D Kahan
Aug 29, 1998·Clinical Biochemistry·D J TrepanierR W Yatscoff
May 24, 2000·Clinical Therapeutics·H U Meier-Kriesche, B Kaplan
Dec 24, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Weikang TaoLaura Sepp-Lorenzino
Jun 15, 1999·Journal of Cardiovascular Pharmacology·S E BurkeC D Wegner
Sep 26, 2001·Current Opinion in Critical Care·B D Kahan, S M Koch
Jul 9, 2004·Transplantation·Shuang BaiLane J Brunner
Jan 1, 1997·Drug Metabolism and Drug Interactions·D W Holt, A Johnston
Aug 29, 2001·Clinical Pharmacokinetics·K Mahalati, B D Kahan
Apr 17, 2004·Clinical Pharmacokinetics·Catherine C Crone, Geoffrey M Gabriel
Jul 21, 2005·Clinical Pharmacokinetics·Sunita Bond StentonMary H H Ensom
Nov 24, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·S M Tsunoda, F T Aweeka
Feb 5, 2008·Pharmacogenomics·Dany AnglicheauEric Thervet
Sep 10, 2014·ELife·Zachary A KnightJeffrey M Friedman
Nov 24, 1999·Clinical Therapeutics·L M ShawR W Yatscoff
Feb 3, 2015·Expert Opinion on Drug Delivery·Saba KhanJaved Ali
Feb 15, 2016·Journal of Pharmaceutical and Biomedical Analysis·Adriana Mika, Piotr Stepnowski
Jan 27, 2015·Journal of Clinical Apheresis·Pallavi GaleraRobert Weinstein
Feb 10, 2012·The Journal of Surgical Research·Alwine KistGreg J Barritt
Aug 12, 2009·International Journal of Pharmaceutics·XiaWei WeiZhiYong Qian
Apr 13, 2007·Clinical Biochemistry·David A ColantonioWilliam Clarke
Feb 15, 2005·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Dany AnglicheauEric Thervet
Jan 13, 2005·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Titte R SrinivasBruce Kaplan
Jul 27, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Mercedes FernandezJaime Bosch
Nov 27, 2014·AAPS PharmSciTech·Kishore CholkarAshim K Mitra
Jan 1, 2012·CPT: Pharmacometrics & Systems Pharmacology·K WuR R Bies
Nov 16, 2010·Biomedical Chromatography : BMC·R Nageswara RaoSachin B Agwane
May 1, 2014·Clinical Pharmacology in Drug Development·Huifen Faye WangSeth Schulman
Feb 9, 2010·Transplant International : Official Journal of the European Society for Organ Transplantation·Matthew R WeirBarry D Kahan
Jun 9, 2015·Drug Discovery Today·Dirk Jan A R MoesJohan W de Fijter

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

International Journal of Pharmaceutics
P SimamoraS H Yalkowsky
Transplantation
R W YatscoffP Chackowsky
The New England Journal of Medicine
Giovanni StalloneGiuseppe Grandaliano
© 2021 Meta ULC. All rights reserved